Lexicon Pharmaceuticals, Inc. (LXRX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.78
- As of
Kresmion compiles this page from LXRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
LEXICON PHARMACEUTICALS, INC. (LXRX): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-05.
See the full LXRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LXRX on one page. Preview it with sample data, then open it live with a free account.
Preview the LXRX dossierActive events for LXRX
- mediumEarnings above estimates
Q3-2026: Beat consensus by 49.4%, EPS $-0.03 vs $-0.0593 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 79% of LXRX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +333% to LXRX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +1777% to LXRX (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 77% of LXRX (2026Q2)
FREE, NO ACCOUNT
Every event on LXRX, as it fires
You are seeing 5 of 15 events recorded on LXRX since 2026-05-29.
The five above landed across 2 days. The other 10 were recorded on 3 other days. 8 of the 15 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
LXRX positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| Point72 Asset Management, L.P. FundCUSIP 528872302 · 2026Q2 | $19.8M | 0.03% |
| CITADEL ADVISORS LLC FundCUSIP 528872302 · 2026Q2 | $3.8M | 0.00% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 528872302 · 2026Q2 | $2.7M | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 528872302 · 2026Q2 | $2.7M | 0.00% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 528872302 · 2026Q2 | $1.5M | 0.00% |
| D. E. Shaw & Co., Inc. FundCUSIP 528872302 · 2026Q2 | $53K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LXRX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
More data on LXRX
LXRX against its peers
LXRX's operating margin of -98.2% ranks in the 64th percentile of 6 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2025-12-31.
| Metric | LXRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 49.8M USD | 62.1M USD | 50 | 6 |
| Operating margin | -98.2% | -158.7% | 64 | 6 |
| Net margin | -101.1% | -152.4% | 64 | 6 |
| Return on equity | -46.8% | -53.8% | 58 | 17 |
Peers (18): XOMA.D, SGMT, SANA, WVE, ACHV, ANNX, CGEM, SLDB, FDMT, AVBP, AURA, ARDX, IMMX, CADL, HELP, CRVS, MGTX, PRME. Left out: ATTO (no annual filing), BBTX (no annual filing), APMD (no annual filing), LTGO (no annual filing), OBX (no annual filing), ANL (period gap), AKTS (no annual filing). Fiscal periods ending between 2025-03-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (LXRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in LXRX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on LXRX in the last 180 days.
Upstream: SEC EDGAR filings for LXRX
Kresmion, "LEXICON PHARMACEUTICALS, INC. (LXRX) institutional holdings and SEC filings", data as of 2026-11-08, https://kresmion.com/research/LXRX. Upstream data: SEC EDGAR filings for LXRX.
Link to this data (HTML):
<a href="https://kresmion.com/research/LXRX">LEXICON PHARMACEUTICALS, INC. (LXRX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow LXRX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to LXRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.